Posts

Posted on

Marriott Vacations Worldwide Corporation to Present at the Barclays Eat, Sleep, Play Conference on December 2, 2020

PR Newswire

ORLANDO, Fla., Nov. 13, 2020 /PRNewswire/ — Marriott Vacations Worldwide Corporation (NYSE: VAC) announced today that John Geller, executive vice president and chief financial and administrative officer, will participate in a fireside chat at the Barclays Eat, Sleep, Play Conference on Wednesday, December 2, 2020 at 1:00 p.m. ET.

A live webcast will be available in the Investor Relations section of the company’s website at ir.mvwc.com. The webcast will also be available on the company’s website for 30 days following the call.


About Marriott Vacations Worldwide Corporation


Marriott Vacations Worldwide Corporation is a leading global vacation company that offers vacation ownership, exchange, rental and resort and property management, along with related businesses, products and services. The company has a diverse portfolio that includes seven vacation ownership brands. It also includes exchange networks and membership programs, as well as management of other resorts and lodging properties. As a leader and innovator in the vacation industry, the company upholds the highest standards of excellence in serving its customers, investors and associates while maintaining exclusive, long-term relationships with Marriott International and Hyatt Hotels Corporation for the development, sales and marketing of vacation ownership products and services. For more information, please visit www.marriottvacationsworldwide.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/marriott-vacations-worldwide-corporation-to-present-at-the-barclays-eat-sleep-play-conference-on-december-2-2020-301172135.html

SOURCE Marriott Vacations Worldwide

Posted on

Gabelli Utility Trust Continues Monthly Distributions, Declaring Distributions of $0.05 Per Share

Gabelli Utility Trust Continues Monthly Distributions, Declaring Distributions of $0.05 Per Share

RYE, N.Y.–(BUSINESS WIRE)–
The Board of Trustees of The Gabelli Utility Trust (NYSE:GUT) (the “Fund”) approved the continuation of its policy of paying fixed monthly cash distributions. The Board of Trustees declared cash distributions of $0.05 per share for each of January, February, and March 2021.

 

Distribution Month

Record Date

Payable Date

January

January 14, 2021

January 22, 2021

February

February 11, 2021

February 19, 2021

March

March 17, 2021

March 24, 2021

Additionally, the Board of Trustees continues to evaluate potential strategic opportunities for the Fund in what we believe to be an attractive environment to invest in the broader equity markets.

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the monthly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund. The Gabelli Utility Trust has paid a distribution to shareholders every month since October 1999.

The Fund’s shares are currently trading at a premium to net asset value. The Board of Trustees believes that the premium at which the Fund shares trade relative to net asset value is not likely to be sustainable. Shareholders participating in the Fund’s dividend reinvestment plan should note that at the current market price, the reinvestment of distributions occurs at a premium to net asset value.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2020 would include approximately 1% from net investment income and 99% would be deemed a return of capital on a book basis. The source of the distributions will likely change due to investment activity through the end of the calendar year and this information does not represent what should be reported for tax purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2020 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2020 distributions in early 2021 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. More information regarding the Fund’s distribution policy and other information about the Fund is available by calling 800-GABELLI (800-422-3554) or visiting www.gabelli.com.

About The Gabelli Utility Trust

The Gabelli Utility Trust is a diversified, closed-end management investment company with $328 million in total net assets whose primary investment objective is to seek long-term growth of capital and income by investing primarily in utility companies involved in the generation and distribution of electricity, gas, and water. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL).

NYSE – GUT

CUSIP – 36240A101

Investor Relations:

David Schachter

(914} 921-5057

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Lineage Cell Therapeutics Proudly Supports Patients’ Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14

Lineage Cell Therapeutics Proudly Supports Patients’ Access to Innovative Cell Therapy Treatments and Research Through Passage of Proposition 14

 Voters Authorize California Institute for Regenerative Medicine to Fund $5.5 Billion in Grants for Stem Cell Research and Development

CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, strongly endorses the recent passing of Proposition 14 in California. This bill will enhance patients’ access to groundbreaking stem cell therapy treatments by authorizing the California Institute for Regenerative Medicine (CIRM) the ability to fund up to $5.5 billion in grants to support therapeutic development, medical research, and facilities based on stem cell technologies. This initiative builds upon the success of Proposition 71, which issued approximately $3 billion for the funding of stem cell research and led to important medical advances, including functional cures in some patients receiving cell therapy treatments. The development of Lineage’s OPC1 oligodendrocyte progenitor cell therapy for the treatment of acute spinal cord injury (SCI), was one of the first clinical trials supported by CIRM and has showed durable and encouraging results in some patients.

“At Lineage, the patients and their families inspire us to advance cell therapy products and this recent approval of Proposition 14 ensures that access to cutting edge cell-based therapies can continue from companies like ours,” stated Brian M. Culley, Lineage CEO. “Cell therapy has the ability to make a profound impact on millions of lives and the passage of Proposition 14 reflects California’s serious commitment to supporting innovative local companies through the expensive and time-consuming process required to discover and test new cell-based therapies and will drive further innovation in stem cell development and research. Of note, our clinical study of OPC1 for the treatment of acute spinal cord injury was one of the first cell therapy clinical trials supported by CIRM under Prop 71. It was tremendously meaningful for some of our patients’ success stories to be featured in the Prop 14 campaign this year, along with others who have experienced life-changing benefits from stem cell therapy innovation in California. We are extremely thankful to CIRM for their partnership and valuable contributions, not only to Lineage, but also for other companies working in this exciting and rapidly growing field. We believe that all three of our clinical-stage programs could be considered for future grant funding under this new initiative.”

About OPC1

OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements to motor recovery in individuals with acute spinal cord injuries (SCI). OPCs are naturally occurring precursors to the cells which provide electrical insulation for nerve axons in the form of a myelin sheath. SCI occurs when the spinal cord is subjected to a severe crush or contusion injury and typically results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder control and other body functions. There are approximately 18,000 new spinal cord injuries annually in the U.S. and there currently are no FDA-approved drugs specifically for the treatment of SCI. The OPC1 program has been partially funded by a $14.3 million grant from the California Institute for Regenerative Medicine. OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA).

About the OPC1 Clinical Study

The SCiStar Study of OPC1 is an open-label, 25-patient, single-arm trial testing three sequential escalating doses of OPC1 which was administered 21 to 42 days post-injury, at up to 20 million OPC1 cells in patients with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) acute spinal cord injuries (SCI). These individuals had experienced severe paralysis of the upper and lower limbs. The primary endpoint in the SCiStar study was safety as assessed by the frequency and severity of adverse events related to OPC1, the injection procedure, and immunosuppression with short-term, low-dose tacrolimus. Secondary outcome measures included neurological functions measured by upper extremity motor scores (UEMS) and motor level on International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examinations through 365 days post-treatment. Enrollment is complete in this study; patients will continue to be evaluated on a long-term basis.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s expected eligibility for grants. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the Securities and Exchange Commission (the SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s Annual Report on Form 10-K filed with the SEC on March 12, 2020 and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

([email protected])

(442) 287-8963

Solebury Trout IR

Gitanjali Jain Ogawa

([email protected])

(646) 378-2949

Russo Partners – Media Relations

Nic Johnson or David Schull

[email protected]

[email protected]

(212) 845-4242

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo
Logo
Posted on

Trio-Tech Reports First Quarter Results

Trio-Tech Reports First Quarter Results

VAN NUYS, Calif.–(BUSINESS WIRE)–Trio-Tech International (NYSE MKT: TRT) today announced financial results for the first quarter of fiscal 2021 ended September 30, 2020.

Total revenue for the three months ended September 30, 2020 decreased 30% to $6,841,000. This compares to total revenue of $9,823,000 for the first quarter of fiscal 2020. Revenue in each of the Company’s operating segments — manufacturing, testing services, and distribution — decreased in this year’s first quarter versus the same period of last fiscal year, primarily reflecting the impact of the global Covid-19 pandemic.

Overall gross margin decreased to $1,518,000, or 22% of revenue, compared to $2,252,000, or 23% of revenue, for the first quarter last fiscal year.

Operating expenses for the first quarter of fiscal 2021 decreased 9% to $1,845,000, or 27% of revenue, compared to $2,030,000, or 21% of revenue, for the first quarter of fiscal 2020.

The operating loss for this year’s first quarter was $327,000. This compares to operating income of $222,000 for the same quarter a year ago.

Total other income was $174,000 for the first quarter of fiscal 2021 compared to $42,000 for the same quarter last year. Other income for this year’s first quarter included government assistance of $142,000 for Trio-Tech’s Singapore and Malaysia operations to mitigate the adverse impact on the business from the pandemic. There was no such assistance in the same quarter last year.

The net loss for the first quarter of fiscal 2021 was $8,000, or $0.00 per share. This compares to net income for the first quarter of fiscal 2020 of $273,000, or $0.07 per diluted share.

Shareholders’ equity at September 30, 2020 was $25,538,000, or $6.93 per outstanding share, compared to $25,146,000, or $6.84 per outstanding share, at June 30, 2020. There were approximately 3,685,555 and 3,673,055 common shares outstanding at September 30, 2020 and June 30, 2020, respectively.

CEO Comments

S.W. Yong, Trio-Tech’s CEO, said, “The global Covid-19 pandemic had a dramatic impact on Trio-Tech’s first quarter performance. While we posted a small net loss in this difficult operating environment, our significant accomplishments include improvements in gross margins in the manufacturing and distribution segments and positive cash flow for the quarter. As the pandemic has yet to run its course, we will continue to adjust operating expenses wherever possible to insure Trio-Tech’s future success.”

About Trio‑Tech

Established in 1958, Trio-Tech International is located in Van Nuys, California, with its Principal Executive Office and regional headquarter in Singapore. Trio-Tech International is a diversified business group with interests in semiconductor testing services, manufacturing and distribution of semiconductor testing equipment, and real estate. Our subsidiary locations include Tianjin, Suzhou, Chongqing in China, as well as Kuala Lumpur Malaysia and Bangkok Thailand. Further information about Trio-Tech’s semiconductor products and services can be obtained from the Company’s Web site at www.triotech.com and www.universalfareast.com.

Forward Looking Statements

This press release contains statements that are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and assumptions regarding future activities and results of operations of the Company. In light of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the following factors, among others, could cause actual results to differ materially from those reflected in any forward looking statements made by or on behalf of the Company: market acceptance of Company products and services; changing business conditions or technologies and volatility in the semiconductor industry, which could affect demand for the Company’s products and services; the impact of competition; problems with technology; product development schedules; delivery schedules; changes in military or commercial testing specifications which could affect the market for the Company’s products and services; difficulties in profitably integrating acquired businesses, if any, into the Company; risks associated with conducting business internationally and especially in Asia, including currency fluctuations and devaluation, currency restrictions, local laws and restrictions and possible social, political and economic instability; changes in U.S. and global financial and equity markets, including market disruptions and significant interest rate fluctuations; public health issues related to the COVID-19 pandemic; and other economic, financial and regulatory factors beyond the Company’s control. Other than statements of historical fact, all statements made in this Quarterly Report are forward looking, including, but not limited to, statements regarding industry prospects, future results of operations or financial position, and statements of our intent, belief and current expectations about our strategic direction, prospective and future financial results and condition. In some cases, you can identify forward looking statements by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential,” “believes,” “can impact,” “continue,” or the negative thereof or other comparable terminology. Forward looking statements involve risks and uncertainties that are inherently difficult to predict, which could cause actual outcomes and results to differ materially from our expectations, forecasts and assumptions.

TRIO‑TECH INTERNATIONAL AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

UNAUDITED (IN THOUSANDS, EXCEPT EARNINGS PER SHARE)

 

 

 

Three Months Ended

 

September 30,

 

 

 

 

Revenue

2020

 

2019

 

 

 

Manufacturing

$

2,625

 

$

3,317

 

Testing services

 

2,954

 

 

4,390

 

Distribution

 

1,258

 

 

2,099

 

Real estate

 

4

 

 

17

 

 

 

 

 

 

6,841

 

 

9,823

 

Cost of Sales

 

 

Cost of manufactured products sold

 

1,937

 

 

2,555

 

Cost of testing services rendered

 

2,322

 

 

3,191

 

Cost of distribution

 

1,047

 

 

1,807

 

Cost of real estate

 

17

 

 

18

 

 

 

 

 

 

5,323

 

 

7,571

 

 

 

 

Gross Margin

 

1,518

 

 

2,252

 

 

 

 

Operating Expenses:

 

 

General and administrative

 

1,660

 

 

1,788

 

Selling

 

111

 

 

190

 

Research and development

 

75

 

 

76

 

Gain on disposal of property, plant and equipment

 

(1

)

 

(24

)

 

 

 

Total operating expenses

 

1,845

 

 

2,030

 

 

 

 

(Loss) Income from Operations

 

(327

)

 

222

 

 

 

 

Other Income (Expenses)

 

 

Interest expenses

 

(37

)

 

(68

)

Other income, net

 

211

 

 

110

 

 

 

 

Total other income

 

174

 

 

42

 

 

 

 

(Loss) Income from Continuing Operations before Income Taxes

 

(153

)

 

264

 

Income Tax Expense

 

(7

)

 

—

 

 

 

 

(Loss) Income from Continuing Operations before Non-controlling Interest, net of tax

 

(160

)

 

264

 

 

 

 

Loss from discontinued operations, net of tax

 

(6

)

 

(1

)

 

 

 

NET (LOSS) INCOME

 

(166

)

 

263

 

 

 

 

Less: Net loss attributable to the non-controlling interest

 

(158

)

 

(10

)

 

 

 

Net (Loss) Income attributable to Trio-Tech International

 

(8

)

 

273

 

 

 

 

Net (Loss) Income Attributable to Trio-Tech International:

 

 

(Loss) Income from continuing operations, net of tax

 

(5

)

 

274

 

Loss from discontinued operations, net of tax

 

(3

)

 

(1

)

 

 

 

Net (Loss) Income Attributable to Trio-Tech International

$

(8

)

$

273

 

 

 

 

Earnings per share

 

 

Basic earnings per share

$

0.00

 

$

0.07

 

 

 

 

Diluted earnings per share

$

0.00

 

$

0.07

 

 

 

 

Weighted Average Shares Outstanding – Basic

 

3,686

 

 

3,673

 

Weighted Average Shares Outstanding – Diluted

 

3,766

 

 

3,690

 

TRIO‑TECH INTERNATIONAL AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

UNAUDITED (IN THOUSANDS, EXCEPT EARNINGS PER SHARE)

 

 

 

Three Months Ended

 

September 30,

 

2020

 

 

2019

 

 

 

Comprehensive (Loss) Income Attributable to Trio-Tech International:

 

 

 

 

 

Net (loss) income

$

(166

)

$

263

 

Foreign currency translation, net of tax

 

640

 

 

(563

)

 

 

 

Comprehensive Income (Loss)

 

474

 

 

(300

)

 

 

 

Less: comprehensive (loss) income attributable to non-controlling interests

 

(122

)

 

9

 

 

 

 

Comprehensive Income (Loss) Attributable to Trio-Tech International

$

596

 

$

(309

)

TRIO‑TECH INTERNATIONAL AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT NUMBER OF SHARES)

 

 

 

 

 

 

Sep. 30,

 

 

Jun. 30,

2020

 

 

2020

ASSETS

(Unaudited)

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

Cash and cash equivalents

$

4,849

 

$

4,150

Short-term deposits

 

6,678

 

 

6,697

Trade accounts receivable, net

 

5,745

 

 

5,951

Other receivables

 

905

 

 

998

Inventories, net

 

1,872

 

 

1,922

Prepaid expenses and other current assets

 

417

 

 

482

 

 

 

 

Total current assets

 

20,466

 

 

20,200

 

 

 

 

Deferred tax assets

 

276

 

 

247

Investment properties, net

 

699

 

 

690

Property, plant and equipment, net

 

10,135

 

 

10,310

Operating lease right-of-use assets

 

819

 

 

944

Other assets

 

1,738

 

 

1,609

Restricted term deposits

 

1,695

 

 

1,660

 

 

 

 

Total non-current assets

 

15,362

 

 

15,460

 

 

 

 

TOTAL ASSETS

$

35,828

 

$

35,660

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

Lines of credit

$

—

 

$

172

Accounts payable

 

2,024

 

 

2,590

Accrued expenses

 

3,549

 

 

3,005

Income taxes payable

 

360

 

 

344

Current portion of bank loans payable

 

425

 

 

370

Current portion of finance leases

 

224

 

 

231

Current portion of operating leases

 

425

 

 

477

Current portion of PPP loan

 

121

 

 

54

 

 

 

 

Total current liabilities

 

7,128

 

 

7,243

 

 

 

 

Bank loans payable, net of current portion

 

1,956

 

 

1,836

Finance leases, net of current portion

 

394

 

 

435

Operating leases, net of current portion

 

394

 

 

467

Income taxes payable

 

385

 

 

430

PPP loan, net of current portion

 

—

 

 

67

Other non-current liabilities

 

33

 

 

36

 

 

 

 

Total non-current liabilities

 

3,162

 

 

3,271

 

 

 

 

TOTAL LIABILITIES

 

10,290

 

 

10,514

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

TRIO-TECH INTERNATIONAL’S SHAREHOLDERS’ EQUITY:

 

 

 

Common stock, no par value, 15,000,000 shares authorized; 3,685,555 and 3,673,055 shares

 

 

 

issued and outstanding at September 30, 2020 and June 30, 2020, respectively

 

11,458

 

 

11,424

Paid-in capital

 

3,369

 

 

3,363

Accumulated retained earnings

 

8,028

 

 

8,036

Accumulated other comprehensive gain-translation adjustments

 

1,747

 

 

1,143

 

 

 

 

Total Trio-Tech International shareholders’ equity

 

24,602

 

 

23,966

 

 

 

 

Non-controlling interest

 

936

 

 

1,180

 

 

 

 

TOTAL EQUITY

 

25,538

 

 

25,146

 

 

 

 

TOTAL LIABILITIES AND EQUITY

$

35,828

 

$

35,660

 

Company Contact:

A. Charles Wilson

Chairman

(818) 787-7000

Investor Contact:

Berkman Associates

(310) 927-3108

[email protected]

KEYWORDS: California Singapore United States North America Asia Pacific

INDUSTRY KEYWORDS: Other Manufacturing Technology Semiconductor Public Relations/Investor Relations Oil/Gas Communications Manufacturing Energy Hardware

MEDIA:

Posted on

The Peck Company Holdings to Participate at Benchmark Company’s 9th Annual Discovery 1×1 Investor Conference

The Peck Company Holdings to Participate at Benchmark Company’s 9th Annual Discovery 1×1 Investor Conference

Virtual Meetings to be Held on Wednesday, November 18

BURLINGTON, Vt.–(BUSINESS WIRE)–
The Peck Company Holdings, Inc. (NASDAQ: PECK) (the “Company” or “Peck”), a leading commercial solar engineering, procurement and construction (EPC) company, today announced that Jeff Peck, Chief Executive Officer, John Sullivan, Chief Financial Officer, and Michael D’Amato, Chief Strategy Officer, will participate at Benchmark Company’s 9th Annual Discovery 1×1 Investor Conference. The virtual event will take place on Wednesday, November 1 8, 2020 with virtual 1×1 investor meetings throughout the day.

To schedule a meeting with management, please contact your Benchmark Company representative or Vince Curatola at [email protected] or [email protected].

About Benchmark Company

Benchmark Company is an institutionally focused research, sales & trading and investment banking firm working to set the benchmark in promoting each client’s success.

For additional information, please visit https://www.benchmarkcompany.com.

About The Peck Company Holdings, Inc.

Headquartered in South Burlington, VT, The Peck Company Holdings, Inc. is a 2nd-generation family business founded in 1972 and rooted in values that align people, purpose, and profitability. Ranked by Solar Power World as one of the leading commercial solar contractors in the Northeastern United States, the Company provides EPC services to solar energy customers for projects ranging in size from several kilowatts for residential properties to multi-megawatt systems for large commercial and utility scale projects. The Company has installed over 125 megawatts worth of solar systems since it started installing solar in 2012 and continues its focus on profitable growth opportunities. Please visit www.peckcompany.com for additional information.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words or phrases such as “may,” “should,” “expects,” “could,” “intends,” “plans,” “anticipates,” “estimates,” “believes,” “forecasts,” “predicts” or other similar expressions are intended to identify forward-looking statements, which include, without limitation, earnings forecasts, effective tax rate, statements relating to our business strategy and statements of expectations, beliefs, future plans and strategies and anticipated developments concerning our industry, business, operations and financial performance and condition.

The forward-looking statements included in this press release are based on our current expectations, projections, estimates and assumptions. These statements are only predictions, not guarantees. Such forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict. These risks and uncertainties may cause actual results to differ materially from what is forecast in such forward-looking statements, and include, without limitation, the risk factors described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

All forward-looking statements included in this press release are based on information currently available to us, and we assume no obligation to update any forward-looking statement except as may be required by law.

Michael d’Amato

[email protected]

p802-264-2040

ClearThink

[email protected]

KEYWORDS: United States North America Vermont

INDUSTRY KEYWORDS: Alternative Energy Energy Environment Other Energy Utilities

MEDIA:

Posted on

New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration

New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration

— Presentation during American Academy of Ophthalmology Annual Meeting (AAO 2020 Virtual) demonstrates clinical improvement in the less severe eye —

— Additional data from OPTIC 48-week follow-up study and OPTIC-X extension trial, including findings showing that the majority of TEPEZZA patients who were diplopia (double vision) responders in OPTIC at week 24 maintained their response at week 72, nearly a year off-treatment —

— Patients who received placebo during the OPTIC Phase 3 clinical trial and then received TEPEZZA in the OPTIC-X extension trial also achieved clinically significant diplopia improvement with an average of 12 months of disease, compared with six months in OPTIC —

DUBLIN–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new TEPEZZA® (teprotumumab-trbw) data presented at the American Academy of Ophthalmology Annual Meeting (AAO 2020 Virtual), including findings suggesting benefits of TEPEZZA in the less severe eye of patients with Thyroid Eye Disease (TED), and new data from theOPTIC 48-week follow-up study and OPTIC-X clinical trial. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of TED – a serious, progressive and vision-threatening rare autoimmune disease.1

“We continue to analyze our existing clinical trials and pursue new research to fully understand the impact TEPEZZA has on this challenging disease,” said Elizabeth H.Z. Thompson, Ph.D., group vice president, development and external search, Horizon. “Our data demonstrating the effect of TEPEZZA at varying stages of the disease, including in the less severely affected eye and in patients who have had Thyroid Eye Disease for a longer period of time, will help advance the science of Thyroid Eye Disease and instill greater understanding of the role TEPEZZA can play in improving patient outcomes.”

Compelling Response in Less Severe TED

Improvement in Fellow Eye of Patients with TED: Pooled Analyses from Teprotumumab Studies (PO305)

In patients with TED, one eye can have more severe symptoms than the other. The TEPEZZA Phase 2 clinical trial and OPTIC Phase 3 confirmatory clinical trial designated the more severely affected eye as the “study eye”.2,3 This new analysis focused specifically on efficacy of TEPEZZA in treating the less severe eye, or “fellow eye”, of patients in the TEPEZZA Phase 2 and 3 trials. Researchers analyzed the intent-to-treat (ITT) population in the Phase 2 and Phase 3 studies, defined as all patients randomized to receive TEPEZZA (n=84) and all patients randomized to receive placebo (n=87). The fellow eye was less proptotic than the study eye in both the TEPEZZA (21.61 mm vs. 23.02 mm) and placebo (21.97 mm vs. 23.15 mm) groups, indicating less severe disease. Additionally, the fellow eye, on average, demonstrated less inflammation based on the clinical activity score (CAS) than the study eye in both the TEPEZZA (CAS: 4.3 vs. 5.1 points) and placebo (CAS: 4.7 vs. 5.3 points) groups.

Findings suggest that TEPEZZA may offer benefits in patients with less severe TED:

  • At Week 24, more TEPEZZA patients were proptosis (eye bulging) responders (≥2 mm reduction) in the fellow eye than placebo patients (63.1 percent vs. 8.0 percent, p<0.001), with a mean reduction in proptosis of 2.39 mm for TEPEZZA patients and a mean increase in proptosis of 0.15 mm for placebo patients (p<0.001).
  • 30 patients (34.5 percent) in the placebo group had a worsening of proptosis at Week 24 in the fellow eye compared to 0 patients (0 percent) in the TEPEZZA group.
  • CAS in the fellow eye decreased from baseline by a mean of -3.42 points in the TEPEZZA group compared to -2.00 points in the placebo group (p<0.001) at Week 24.
  • More TEPEZZA patients (63.1 percent) than placebo patients (26.4 percent) had a CAS of 0 or 1 – signifying disease inactivation – in the fellow eye at Week 24 (p<0.001).

“We know from the clinical development program that TEPEZZA significantly reduces proptosis and Thyroid Eye Disease-related inflammation in patients with moderate-to-severe disease, and now with this new analysis of the Phase 2 and 3 data, we have evidence pointing to efficacy in patients with less severe disease as well,” said Raymond Douglas, M.D., Ph.D., study author and director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center. “We believe this robust effect is the result of the mechanism of TEPEZZA that effectively targets the underlying molecular pathways that cause Thyroid Eye Disease.”

Additional Findings from the OPTIC 48-Week Follow-Up Study and OPTIC-X Clinical Trial

Long Term Assessment of Proptosis and Diplopia from the OPTIC Trial of Teprotumumab in Thyroid Eye Disease (PA038)

Additional data from the OPTIC Phase 3 confirmatory clinical trial and the OPTIC-X open-label extension clinical trial were also included in an abstract and presented during AAO, supplementing the topline results on proptosis response announced in July 2020. The OPTIC trial included a 24-week treatment period (treatment every three weeks for a total of eight infusions) and a 48-week off-treatment follow-up period. OPTIC-X evaluated TEPEZZA in patients who were enrolled in OPTIC and were either proptosis non-responders at Week 24 or were proptosis responders at Week 24 but flared during the 48-week off-treatment follow-up period.

New OPTIC 48-week off-treatment follow-up study findings include the following:

  • The majority of TEPEZZA patients who had at least 1 grade of diplopia (double vision) improvement at Week 24 in OPTIC maintained their response at Week 72 (11/19; 58 percent) without receiving additional TED treatment.
  • 50 percent of TEPEZZA patients (8/16) who had a diplopia score of 0 at Week 24 in OPTIC maintained a diplopia score of 0 at Week 72 without receiving additional TED treatment.

New OPTIC-X findings include the following:

  • 61 percent of patients (14/23) who received placebo during the OPTIC trial and then entered OPTIC-X and received TEPEZZA were considered diplopia responders (≥1 grade improvement) at Week 24. This is consistent with results from the OPTIC trial, where 68 percent of patients (19/28) who received TEPEZZA had a change from baseline of at least 1 grade in diplopia at Week 24. OPTIC-X patients had an average of 12 months of TED compared with six months in OPTIC.
  • Five patients who received placebo during the OPTIC trial and then entered OPTIC-X had a CAS of 0 or 1, which means they had minimal or no inflammation. Of those, 60 percent (3/5) were proptosis responders at Week 24 (≥2 mm improvement in proptosis from baseline in the study eye without deterioration in the fellow eye at Week 24).

There were no new safety concerns in OPTIC-X or the OPTIC 48-week off-treatment follow-up period, including in patients who received additional TEPEZZA treatment.

About Thyroid Eye Disease (TED)

TED is a serious, progressive and vision-threatening rare autoimmune disease.1 TED often occurs in people living with hyperthyroidism or Graves’ disease; however, it is a distinct disease that is caused by autoantibodies activating an IGF-1R-mediated signaling complex on cells within the retro-orbital space.4,5 This leads to a cascade of negative effects, which may cause long-term, irreversible damage. As TED progresses, the serious damage it can cause includes proptosis (eye bulging), strabismus (misalignment of the eyes) and diplopia (double vision) – and in some cases can lead to blindness.6,7

About TEPEZZA

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache and dry skin.

For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the potential benefits of TEPEZZA as a treatment of less severe TED. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks associated with future clinical development, whether TEPEZZA will be adopted as a treatment for less severe TED, as well as those described in Horizon’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

References

  1. Barrio-Barrio J, et al. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmopathy. 2015;2015:1-16.
  2. Smith, et al. Teprotumumab for Thyroid-Associated Ophthalmology. N Engl J Med. 2017;376:1748-1761.
  3. Douglas, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341-352.
  4. Weightman DR, et al. Autoantibodies to IGF-1 Binding Sites in Thyroid Associated Ophthalmopathy. Autoimmunity. 1993;16(4):251–257.
  5. Pritchard J, et al. Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves’ Disease Is Mediated Through the Insulin-Like Growth Factor 1 Receptor Pathway. J Immunol. 2003;170:6348-6354.
  6. Ross DS, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9-26.
  7. McKeag D, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO ) survey. Br J Ophthalmol. 2007;91:455-458.

Tina Ventura

Senior Vice President, Investor Relations

[email protected]

Ruth Venning

Executive Director, Investor Relations

[email protected]

U.S. Media Contacts:

Rachel Vann

Director, Product Communications

[email protected]

Ireland Media Contact:

Gordon MRM

Ray Gordon

[email protected]

KEYWORDS: California Europe Ireland United States North America

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Optical Health Hospitals Genetics

MEDIA:

Logo
Logo
Posted on

Acadia Realty Trust to Present at NAREIT’s REITworld®: 2020 Annual Conference

Acadia Realty Trust to Present at NAREIT’s REITworld®: 2020 Annual Conference

RYE, N.Y.–(BUSINESS WIRE)–
Acadia Realty Trust (NYSE: AKR) (“Acadia” or the “Company”) today announced that it will participate in NAREIT’s REITworld®: 2020 Annual Conference, which will be held from November 17-19, 2020. Kenneth F. Bernstein, President and Chief Executive Officer, is scheduled to make a presentation on Wednesday, November 18 at 4:30 p.m. ET.

To access the Company’s live presentation, attendees are required to register for NAREIT’s REITworld®: 2020 Annual Conference, using the registration link below. The Company’s presentation materials will be posted on its website under “Investors – Presentations & Events.”

Acadia will also host individual virtual meetings with investors during the conference.

Acadia Realty Trust Webcast:

Date:

 

Wednesday, November 18, 2020

Time:

 

4:30 p.m. – 5:00 p.m. ET

Webcast link:

 

REITworld 2020 Annual Conference

Webcast replay expires: 90 days following the live webcast

Acadia’s presentation will be available live via audio webcast, which may be accessed at the above link. A replay of the webcast will be available on the Company’s website for 90 days under “Investors – Presentations & Events.”

The Company uses, and intends to use, the Investors page of its website, which can be found at www.acadiarealty.com, as a means of disclosing material nonpublic information and of complying with its disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the Investors page, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

About Acadia Realty Trust

Acadia Realty Trust is an equity real estate investment trust focused on delivering long-term, profitable growth via its dual – Core and Fund – operating platforms and its disciplined, location-driven investment strategy. Acadia Realty Trust is accomplishing this goal by building a best-in-class core real estate portfolio with meaningful concentrations of assets in the nation’s most dynamic corridors; making profitable opportunistic and value-add investments through its series of discretionary, institutional funds; and maintaining a strong balance sheet. For further information, please visit www.acadiarealty.com.

Safe Harbor Statement

Certain statements in this press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project,” or the negative thereof, or other variations thereon or comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause our actual results and financial performance to be materially different from future results and financial performance expressed or implied by such forward-looking statements, including, but not limited to: (i) economic, political and social uncertainty surrounding the COVID-19 pandemic, including (a) the effectiveness or lack of effectiveness of governmental relief in providing assistance to large and small businesses, including the Company’s tenants, that have suffered significant declines in revenues as a result of mandatory business shut-downs, “shelter-in-place” or “stay-at-home” orders and social distancing practices, as well as individuals adversely impacted by the COVID-19 pandemic, (b) the duration of any such orders or other formal recommendations for social distancing and the speed and extent to which revenues of the Company’s retail tenants recover following the lifting of any such orders or recommendations, (c) the potential impact of any such events on the obligations of the Company’s tenants to make rent and other payments or honor other commitments under existing leases, (d) to the extent we were seeking to sell properties in the near term, significantly greater uncertainty regarding our ability to do so at attractive prices, (e) the potential adverse impact on returns from development and redevelopment projects, and (f) the broader impact of the severe economic contraction and increase in unemployment that has occurred in the short term and negative consequences that will occur if these trends are not quickly reversed; (ii) the ability and willingness of the Company’s tenants (in particular its major tenants) and other third parties to satisfy their obligations under their respective contractual arrangements with the Company; (iii) macroeconomic conditions, such as a disruption of or lack of access to the capital markets; (iv) the Company’s success in implementing its business strategy and its ability to identify, underwrite, finance, consummate and integrate diversifying acquisitions and investments; (v) changes in general economic conditions or economic conditions in the markets in which the Company may, from time to time, compete, and their effect on the Company’s revenues, earnings and funding sources; (vi) increases in the Company’s borrowing costs as a result of changes in interest rates and other factors, including the potential phasing out of the London Interbank Offered Rate after 2021; (vii) the Company’s ability to pay down, refinance, restructure or extend its indebtedness as it becomes due; (viii) the Company’s investments in joint ventures and unconsolidated entities, including its lack of sole decision-making authority and its reliance on its joint venture partners’ financial condition; (ix) the Company’s ability to obtain the financial results expected from its development and redevelopment projects; (x) the ability and willingness of the Company’s tenants to renew their leases with the Company upon expiration, the Company’s ability to re-lease its properties on the same or better terms in the event of nonrenewal or in the event the Company exercises its right to replace an existing tenant, and obligations the Company may incur in connection with the replacement of an existing tenant; (xi) the Company’s liability for environmental matters; (xii) damage to the Company’s properties from catastrophic weather and other natural events, and the physical effects of climate change; (xiii) uninsured losses; (xiv) the Company’s ability and willingness to maintain its qualification as a REIT in light of economic, market, legal, tax and other considerations; (xv) information technology security breaches, including increased cybersecurity risks relating to the use of remote technology during the COVID-19 pandemic; and (xvi) the loss of key executives. The risks described above are not exhaustive and additional factors could adversely affect the Company’s business and financial performance, including the risk factors discussed under the section captioned “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other periodic or current reports the Company files with the SEC. Any forward-looking statements in this press release speak only as of the date hereof. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or change in the events, conditions or circumstances on which such forward-looking statements are based.

Sunny Holcomb

(914) 288-8100

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Residential Building & Real Estate Commercial Building & Real Estate Finance Construction & Property REIT Banking

MEDIA:

Logo
Logo
Posted on

Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform

Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform

NORTH BILLERICA, Mass.–(BUSINESS WIRE)–
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of Lantheus’ artificial intelligence enabled automated bone scan index (aBSI) product on GE Healthcare’s Xeleris platform.

“Lantheus is delighted by the U.S. approval of our digital AI solution for prostate cancer, aBSI, on GE Healthcare’s platform. As a leading multinational medical technology company with deep experience in medical imaging and diagnostics, GE Healthcare presents the ideal attributes to provide global access to this unique digital solution,” said Etienne Montagut, Sr. Vice President of Corporate Development. “aBSI has demonstrated clinical value in quantifying and managing disease progression in advanced prostate cancer patients with the potential to support critical clinical decisions. Lantheus will continue to develop AI solutions to augment and expand the utility of imaging diagnostics for precision medicine in oncology,” Mr. Montagut added.

In October 2019, the Company entered into a global software licensing agreement with GE Healthcare for the rights to aBSI, a vendor neutral stand-alone platform that is enabled with artificial intelligence, which has been trained to automate the detection of hotspots in bone indicative of metastatic disease and calculate the aBSI. The platform offers a fast and reliable alternative to manual interpretation of bone scan images of metastatic prostate cancer. Recent investigations have demonstrated the clinical utility of aBSI as a prognostic and a response imaging biomarker in patients with metastatic prostate cancer.1,2

“The pandemic has proven that data, analytics, AI and connectivity will only become more central to delivering care,” said Erez Levy, General Manager, Nuclear Medicine, GE Healthcare. “For GE Healthcare, that means continuing to advance intelligent and innovative technologies, like aBSI, and deliver precision health to promote better patient outcomes around the world.”

Under the terms of the non-exclusive agreement, GE Healthcare acquired from Lantheus the software license for aBSI for integration into GE Healthcare’s Xeleris platform, excluding the use of aBSI in Japan. Under the agreement with GE Healthcare, Lantheus will receive tiered licensing fees per license sold.

About aBSI

The aBSI product is vendor neutral stand-alone software as a medical device which calculates the automated bone scan index in Technetium-99m bone scintigraphy. aBSI received FDA clearance in 2019 (K191262). The product is enabled with a neural network that has been trained to automate the detection of hotspots and calculate the aBSI value.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.

About GE Healthcare

GE Healthcare is the $16.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “anticipate,” “believe,” “confident,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) the market receptivity to aBSI and to GEHC’s XELERIS platform; (ii) the intellectual property protection of aBSI; and (iii) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

_________________

1 Armstrong AJ, Anand A, Edenbrandt L,et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018 Jul 1;4(7):944-951.

2 Ali A, Hoyle AP, Parker CC, et al. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”. European Urology. 2020 Aug; 3(4): 412-419

Mark Kinarney

Senior Director, Investor Relations

978-671-8842

[email protected]

Melissa Downs

Director, Corporate Communications

646-975-2533

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Research Technology Medical Devices FDA Software Biotechnology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Limestone Bank Introduces Redesigned Website & Improved Digital Experience

Limestone Bank Introduces Redesigned Website & Improved Digital Experience

LOUISVILLE, Ky.–(BUSINESS WIRE)–
Limestone Bank is excited to announce the successful launch of the new LimestoneBank.com. The complete redesign is part of the Bank’s continued efforts to bring innovative banking services to its customers. The new website provides an improved digital experience for both customers and prospective customers alike.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005118/en/

Limestone Bank launches new website, LimestoneBank.com. (Photo: Business Wire)

Limestone Bank launches new website, LimestoneBank.com. (Photo: Business Wire)

The website refresh includes a renewed focus on access to mobile and online banking which provides a secure and convenient way for customers to manage their accounts remotely. Limestone Bank is also proud to announce the expansion of a new service: Curbside Banking, which allows customers that prefer to visit a banking center to conduct a number of transactions from the safety and comfort of their car. This service is now available at seven of Limestone’s banking center locations, with more locations to come in the future. For more information about curbside banking services as well as a list of participating locations, visit LimestoneBank.com/Curbside-Banking.

John T. Taylor, president and chief executive officer of Limestone Bank, knows that improving the digital experience was a crucial next step in the Bank’s growth, saying, “this year has been filled with challenges and hardship for both individuals and businesses but despite all that has changed this year, the need for efficient access to banking services will always remain true, maybe now more than ever. It is our commitment to our customers to adapt to meet their needs.”

Limestone Bank is positioned to continue its ongoing efforts to modernize the traditional banking experience, without abandoning the foundation of community and service the Bank is known for. “It is our commitment to grow with our customers and their ever-evolving needs to ensure that we are providing the exceptional service our customers expect from us—whether that’s an in-person appointment, curbside, on our website, or via one of our many digital banking tools and services,” says Taylor.

Learn more about Limestone Bank’s personal and commercial banking products and services by visiting LimestoneBank.com today.

For more information, please contact Morgan Tiemann at [email protected].

About Limestone Bank, Inc.

Limestone Bank is a Louisville, Kentucky-based bank, wholly owned by Limestone Bancorp, Inc. (NASDAQ: LMST) which operates banking centers in 14 counties throughout the Commonwealth. The Bank’s markets include metropolitan Louisville in Jefferson County and the surrounding counties of Bullitt and Henry and extend south along the Interstate 65 corridor. The Bank serves south central, southern, and western Kentucky from banking centers in Barren, Butler, Daviess, Edmonson, Green, Hardin, Hart, Ohio, and Warren counties. The Bank also has banking centers in Lexington, Kentucky, the second largest city in the state, and Frankfort, Kentucky, the state capital. Limestone Bank is a traditional community bank with a wide range of personal and commercial banking products and services.

Limestone Bank

Morgan Tiemann, 502-499-4778

[email protected]

KEYWORDS: United States North America Kentucky

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Photo
Photo
Limestone Bank launches new website, LimestoneBank.com. (Photo: Business Wire)
Posted on

ePlus Honored with Multiple Awards Including Americas Technology Excellence Partner of the Year for Data Center at Cisco Partner Summit Digital 2020

ePlus Honored with Multiple Awards Including Americas Technology Excellence Partner of the Year for Data Center at Cisco Partner Summit Digital 2020

ePlus also secures Awards for East Region: Software Partner of the Year and Commercial Partner of the Year

HERNDON, Va.–(BUSINESS WIRE)–
ePlus inc. (NASDAQ NGS: PLUS – news) today announced that it is the recipient of a Cisco® Partner Summit Digital Geographical Region award for Americas Technology Excellence Partner of the Year: Data Center. ePlus also received area awards in the East region for Software Partner of the Year and Commercial Partner of the Year. Cisco announced the winners during its annual partner conference, this year held digitally.

Awarded to channel partners who rise to business challenges, the Cisco Partner Summit Digital Global awards are designed to recognize superior business practices and reward best-in-class methodologies. Areas of consideration include innovative processes, architecture-led successes, strategic business outcome-focused programs, seizing new opportunities, and sales approaches.

“Cisco is proud to work together with leading partners to drive digital transformation, creating powerful solutions and fresh approaches to meet the needs of our customers,” said John Moses, vice president, Americas Partner Organization at Cisco. “It is an honor to recognize ePlus with a Cisco Partner Summit Digital Geo-Region award as Technology Excellence Partner of the Year: Data Center, further underscoring its outstanding accomplishments in the Americas.”

“ePlus is honored to be recognized by Cisco for our performance and the assistance we have provided to our customers, helping them achieve positive business outcomes during quite complex and challenging times,” said Darren Raiguel, chief operating officer and president of ePlus Technology. “Our sales and services teams are providing best-in-class guidance, expertise and creativity to enable customer organizations across every industry to succeed in a new and unexpected normal. This level of attention and dedication sets us apart in the industry and we’re also proud that Cisco has recognized our excellence in these areas.”

Cisco Partner Summit Digital Geographical Regional awards reflect the top-performing partners within specific technology markets across the geographical region. All award recipients are selected by a group of Cisco Global Partner Organizations and regional executives.

ePlus is a Cisco Gold Certified Partner with Cisco Master Specializations in Networking, Security, Collaboration, Cloud Builder, and Cloud and Managed Services Master. ePlus is a member of the Cisco Lifecycle Advisor Program as well as the AppDynamics Titan Partnership Program, and holds Cisco Advanced Specializations in Data Center Architecture, Collaboration Architecture, Enterprise Networks Architecture, Service Provider Architecture, Customer Experience, and Security Architecture. In addition, ePlus holds numerous Cisco Authorized Technology Provider designations, as well as a Cisco Gold certification in the UK via its subsidiary IGXGlobal. For more information about Cisco solutions from ePlus, visit www.eplus.com/cisco.

About ePlusinc.

ePlus is a leading consultative technology solutions provider that helps customers imagine, implement, and achieve more from their technology. With the highest certifications from top technology partners and lifecycle services expertise across key areas including security, cloud, data center, collaboration, networking and emerging technologies, ePlus transforms IT from a cost center to a business enabler. Founded in 1990, ePlus has more than 1,400 associates serving a diverse set of customers in the U.S., Europe, and Asia-Pac. The Company is headquartered at 13595 Dulles Technology Drive, Herndon, VA, 20171. For more information, visit www.eplus.com, call 888-482-1122, or email [email protected]. Connect with ePlus on Facebook, LinkedIn, Twitter and Instagram. ePlus, Where Technology Means More®.

ePlus®, Where Technology Means More®, and ePlus products referenced herein are either registered trademarks or trademarks of ePlus inc. in the United States and/or other countries. The names of other companies, products, and services mentioned herein may be the trademarks of their respective owners.

Statements in this press release that are not historical facts may be deemed to be “forward-looking statements.” Actual and anticipated future results may vary materially due to certain risks and uncertainties, including, without limitation, risks related to COVID-19, including but not limited to its possible effects on the availability of and demand for our products and services, our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19, and its impact on the economy, possible adverse effects resulting from financial market disruption and fluctuations in foreign currency rates, and general slowdown of the U.S. economy such as our current and potential customers delaying or reducing technology purchases or put downward pressure on prices, increasing credit risk associated with our customers and vendors, reduction of vendor incentive programs, and restrictions on our access to capital necessary to fund our operations; our ability to consummate and integrate acquisitions; the possibility of goodwill impairment charges in the future; significant adverse changes in, reductions in, or losses of relationships with major customers or vendors; the demand for and acceptance of, our products and services; our ability to adapt our services to meet changes in market developments; our ability to implement comprehensive plans to achieve customer account coverage for the integration of sales forces, cost containment, asset rationalization, systems integration and other key strategies; our ability to reserve adequately for credit losses; our ability to secure our electronic and other confidential information or that of our customers or partners; future growth rates in our core businesses; our ability to protect our intellectual property; the impact of competition in our markets; the possibility of defects in our products or catalog content data; our ability to adapt to changes in the IT industry and/or rapid change in product standards; our ability to realize our investment in leased equipment; our ability to hire and retain sufficient qualified personnel; and other risks or uncertainties detailed in our reports filed with the Securities and Exchange Commission. All information set forth in this press release is current as of the date of this release and ePlus undertakes no duty or obligation to update this information.

Kleyton Parkhurst, SVP

ePlus inc.

[email protected]

703-984-8150

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Online Retail Data Management Retail Technology Software Networks Internet

MEDIA:

Logo
Logo